Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans-Reference-Cited by-同舟云学术

Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans

Published:2015-11-25 Issue:2 Volume:44 Page:209-219
ISSN:1521-009X
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metabolism and Disposition

Author:

Dong J. Q.,Varma M. V.,Wolford A.,Ryder T.,Di L.,Feng B.,Terra S. G.,Sagawa K.,Kalgutkar A. S.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference41 articles.

1. Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport

2. Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac

3. Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice

4. Species differences in drug transporters and implications for translating preclinical findings to humans

5. Late Intervention with a Myeloperoxidase Inhibitor Stops Progression of Experimental Chronic Obstructive Pulmonary Disease

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, in silico, and in vitro evaluation of 7-chloro-quinolines designed as myeloperoxidase inhibitors;Journal of Molecular Structure;2024-09

2. Exploring the role of myeloperoxidase in the atherosclerotic process in hypoxic mice based on the MAPK signaling pathway;Biochemical Pharmacology;2024-07

3. Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study;Heliyon;2024-06

4. Intraplaque Myeloperoxidase Activity as Biomarker of Unstable Atheroma and Adverse Clinical Outcomes in Human Atherosclerosis;JACC: Advances;2023-05

5. Discovery of a novel, highly potent and orally bioavailable pyrrolidinone indole series of irreversible Myeloperoxidase (MPO) inhibitors;Biochemical Pharmacology;2023-03